GNW-Adhoc: Biognosys presents innovative workflow for in-depth and reproducible plasma proteomics, enabling breakthroughs in molecular…

^* The novel, fully automated workflow represents a new

Method of choice for mass spectrometric single-shot plasma analysis

without fractionation

* Bead-based plasma depletion technology enables robust,

reproducible and high-throughput quantification of almost

4,000 proteins in human plasma

* Biognosys brings this advanced workflow to researchers

Life Sciences via the company’s TrueDiscovery(TM)

Research service platform available

HOUSTON, June 08, 2023 (GLOBE NEWSWIRE) — Biognosys, a leading innovator

and provider of proteomics solutions, announces today at the American Society for

Mass Spectrometry (ASMS) Annual Conference

(https://www.asms.org/conferences/annual-conference) introducing a

advanced plasma proteomics offering that provides an in-depth,

enables unbiased analysis of plasma proteins on a large scale.

The novel workflow, which will be released today at 9:50 a.m. CDT as an oral

Presentation at the ASMS session?Industry: Trace Analysis, Quality Control,

and Automation” (industry: trace analysis, quality control and automation)

is presented (https://www.asms.org/docs/default-source/conference/final-

program-detail_2023_as-of-04-23-2023.pdf?sfvrsn=105d72c3_0), includes a

Consistently automated sample preparation, from entering the biological

Sample until generation of peptides suitable for mass spectrometry. through the

Implementation of a fully automated sample processing based on a bead

based, parallel depletion method, Biognosys has one

remarkable 35% reduction in processing time and a reduction

of the time required by 85%. In addition, the use of a bead

based workflow for plasma depletion to a significant

22% increase in protein identification and a robust and

reproducible quantification of almost 4,000 proteins in human

plasma samples allowed.

?Protein depletion is the method of choice for plasma analysis with the

Single-shot mass spectrometry because it preserves protein levels and

highest degree of depth reached without requiring further fractionation

is required,” says Dr. Lukas Reiter, Chief Technology Officer of Biognosys.

?However, conventional depletion methods are limited due to the sequential

Sample preparation time consuming. With our novel bead-based,

parallelized depletion technology, we eliminate this bottleneck and

improve reproducibility at the same time. This breakthrough makes it possible

us, the deepest unadulterated method of discovery with extraordinary

deliver throughput.”

?Blood plasma offers a unique insight into the human body,”

added dr Kristina Beeler, Chief Product Development and Marketing Officer at

Biognosys, adds.?By applying an unbiased approach that

going deeper into the proteome, we discover additional proteins and their

functional variants. This greater depth increases our chances of finding biomarkers

discover that directly reflect relevant biological mechanisms, rather than

to serve only as a backup marker.”

This novel workflow is designed to give researchers a

automated, cost-effective and reproducible solution for the

To provide plasma proteomics and allows scientists to sample more efficiently

to process and obtain reliable results on a large scale.

Biognosys places this advanced workflow over the

proprietary TrueDiscovery(TM) platform to its global customer base

which consists of over 800 biopharmaceutical and academic customers.

About Biognosys

At Biognosys, we believe that deep insight into the proteome is the key to

groundbreaking discoveries that are changing science and changing life

improve. With our versatile portfolio of proteomics solutions the next

generation, including the research service platforms

TrueDiscovery(TM), TrueTarget(TM) and TrueSignature(TM), our flagship software

Spectronaut(®) and the PQ500(TM) kit, we ensure that lessons learned from the

Proteome can be drawn to research, drug development and

to support clinical decision making. Our solutions offer one

multidimensional view of protein expression, function and structure in

all biological species and sample types. Our unique, patented

Technologies use high-resolution mass spectrometry to detect thousands of

proteins with industry-leading precision, depth, and throughput

quantify. Through our strategic partnership with Bruker (Nasdaq:

BRKR) we make proteomics accessible worldwide. Find more information

Visit biognosys.com (http://www.biognosys.com/).

About TrueDiscovery(TM)

Biognosys’ TrueDiscovery platform offers integrated proteomics solutions

for the entire drug development, from the creation of

disease profiles to studies of mechanisms of action and discovery

new biomarker.

TrueDiscovery is based on Hyper Reaction Monitoring (HRM)

Mass spectrometry, an advanced technology co-invented and developed by Biognosys

patented technology for quantifying proteins based on

independent data acquisition (DIA).

TrueDiscovery is the only platform that searches the entire proteome to

Thousands of the most important proteins, including an unlimited number of

Proteoforms to quantify. The platform enables the deepest,

unbiased profiling of tissue and biofluid proteomes

unbeatable specificity on a large scale. The data generated is in high

Dimensions reproducible and easily transferrable to clinical tests. The studies

can be performed in a GLP-certified and GCP-compliant environment

become. For more information, see truediscovery.bio

(http://truediscovery.bio/).

The source language in which the original text is published is the

official and authorized version. Translations get better

communication provided. Only the language version that is in the original

published is legally valid. You should therefore also compare translations

the original language version of the publication.

°

ttn-28